Form 8-K - Current report:
SEC Accession No. 0001785530-25-000030
Filing Date
2025-11-04
Accepted
2025-11-04 07:07:08
Documents
14
Period of Report
2025-11-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K howl-20251104.htm   iXBRL 8-K 30875
2 EX-99.1 a09302025ex991.htm EX-99.1 69999
6 werewolflogohorizontala.jpg GRAPHIC 277881
  Complete submission text file 0001785530-25-000030.txt   615269

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT howl-20251104.xsd EX-101.SCH 1829
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT howl-20251104_lab.xml EX-101.LAB 23449
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT howl-20251104_pre.xml EX-101.PRE 13623
16 EXTRACTED XBRL INSTANCE DOCUMENT howl-20251104_htm.xml XML 2919
Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40366 | Film No.: 251446415
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)